Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Raises $50M

NEW YORK (GenomeWeb) – Synthetic DNA provider Twist Bioscience announced today that it has closed a $50 million private placement.

"We have used our proprietary DNA synthesis platform, which delivers precision at a scale previously not available, to develop a portfolio of diverse products for two large market opportunities — the synthetic biology market through our gene and oligo pool offerings, and the next-generation sequencing market through our exome and custom target enrichment solutions," Twist CEO Emily Leproust said in a statement. "We plan to use a portion of these funds to invest in the emerging vertical market opportunity presented by storing digital data in DNA, as well as forward integration toward drug discovery."

Twist said it has raised $259 million since it was founded in 2013. Last month, the company entered the next-generation sequencing sample prep market with the launch of its first target enrichment products.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.